| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hemolysis | D006461 | 131 associated lipids |
| Tuberculosis | D014376 | 20 associated lipids |
| Stomach Ulcer | D013276 | 75 associated lipids |
| Nocardia Infections | D009617 | 6 associated lipids |
| Diarrhea | D003967 | 32 associated lipids |
| Hearing Loss, Sensorineural | D006319 | 8 associated lipids |
| Otitis Media | D010033 | 12 associated lipids |
| Carcinoma, Basal Cell | D002280 | 6 associated lipids |
| Arrhythmias, Cardiac | D001145 | 42 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Stjepanovic MI et al. | Pulmonary and Vertebral Mycobacterium avium Disease in a HIV-negative 71-year-old Man - A Case Report. | 2016 | Infez Med | pmid:28011973 |
| Ramzy I et al. | GENETIC MUTATIONS AFFECTING THE FIRST LINE ERADICATION THERAPY OF Helicobacter pylori-INFECTED EGYPTIAN PATIENTS. | 2016 | Rev. Inst. Med. Trop. Sao Paulo | pmid:27982354 |
| Gbinigie II and Lasserson D | Clarithromycin-induced akathisia: a class effect of macrolides? | 2016 | BMJ Case Rep | pmid:27927708 |
| Miftahussurur M et al. | Surveillance of Helicobacter pylori Antibiotic Susceptibility in Indonesia: Different Resistance Types among Regions and with Novel Genetic Mutations. | 2016 | PLoS ONE | pmid:27906990 |
| Muñoz-Egea MC et al. | Effect of Antibiotics and Antibiofilm Agents in the Ultrastructure and Development of Biofilms Developed by Nonpigmented Rapidly Growing Mycobacteria. | 2016 | Microb. Drug Resist. | pmid:26208145 |
| Salimi A et al. | Toxicity of macrolide antibiotics on isolated heart mitochondria: a justification for their cardiotoxic adverse effect. | 2016 | Xenobiotica | pmid:26068526 |
| Liou JM et al. | Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. | 2016 | Lancet | pmid:27769562 |
| Campillo A et al. | [10-day triple therapy with esomeprazole 40 mg/12 h vs. quadruple concomitant non-bismuth therapy as first line treatment for Helicobacter pylori infection]. | 2016 | Gastroenterol Hepatol | pmid:27084668 |
| Chauffour A et al. | Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice. | 2016 | PLoS Negl Trop Dis | pmid:27755552 |
| Abuhammour A et al. | Standard triple therapy versus sequential therapy for eradication of Helicobacter pylori in treatment naïve and retreat patients. | 2016 | Arab J Gastroenterol | pmid:27665525 |
| Matsumoto H et al. | Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance. | 2016 | Dig. Dis. Sci. | pmid:27659671 |
| Kasai C et al. | Changes in plasma ghrelin and leptin levels in patients with peptic ulcer and gastritis following eradication of Helicobacter pylori infection. | 2016 | BMC Gastroenterol | pmid:27716077 |
| Gisbert JP | Helicobacter pylori-related diseases. | 2016 | Gastroenterol Hepatol | pmid:27888863 |
| Noda H et al. | A Novel Potassium-Competitive Acid Blocker Improves the Efficacy of Clarithromycin-containing 7-day Triple Therapy against Helicobacter pylori. | 2016 | J Gastrointestin Liver Dis | pmid:27689190 |
| Giorgio F et al. | Helicobacter pylori DNA isolation in the stool: an essential pre-requisite for bacterial noninvasive molecular analysis. | 2016 | Scand. J. Gastroenterol. | pmid:27687850 |
| Donzelli A | Helicobacter pylori Eradication? | 2016 | Gastroenterology | pmid:27590693 |
| Sanches BS et al. | Detection of Helicobacter pylori resistance to clarithromycin and fluoroquinolones in Brazil: A national survey. | 2016 | World J. Gastroenterol. | pmid:27672279 |
| Rossi A et al. | Floating modular drug delivery systems with buoyancy independent of release mechanisms to sustain amoxicillin and clarithromycin intra-gastric concentrations. | 2016 | Drug Dev Ind Pharm | pmid:26065531 |
| Morimoto K et al. | Macrolide-Resistant Mycobacterium avium Complex Lung Disease: Analysis of 102 Consecutive Cases. | 2016 | Ann Am Thorac Soc | pmid:27513168 |
| Christianson S et al. | Time-to-Detection of Inducible Macrolide Resistance in Mycobacterium abscessus Subspecies and Its Association with the Erm(41) Sequevar. | 2016 | PLoS ONE | pmid:27490181 |
| Harada T et al. | Premedication with Clarithromycin Is Effective against Secondary Bacterial Pneumonia during Influenza Virus Infection in a Pulmonary Emphysema Mouse Model. | 2016 | J. Pharmacol. Exp. Ther. | pmid:27489022 |
| Bonfigli AR et al. | Randomized, double-blind, placebo-controlled trial to evaluate the effect of Helicobacter pylori eradication on glucose homeostasis in type 2 diabetic patients. | 2016 | Nutr Metab Cardiovasc Dis | pmid:27480449 |
| Orrin E et al. | Sporotrichoid Mycobacterium chelonae. | 2016 | Australas. J. Dermatol. | pmid:27469486 |
| Yamamoto K et al. | Clarithromycin prevents human respiratory syncytial virus-induced airway epithelial responses by modulating activation of interferon regulatory factor-3. | 2016 | Pharmacol. Res. | pmid:27468646 |
| Ferro BE et al. | Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection. | 2016 | Antimicrob. Agents Chemother. | pmid:27458221 |
| Patton PH et al. | Anti-tuberculous therapy for maintenance of remission in Crohn's disease. | 2016 | Cochrane Database Syst Rev | pmid:27444319 |
| Christl I et al. | Clarithromycin and Tetracycline Binding to Soil Humic Acid in the Absence and Presence of Calcium. | 2016 | Environ. Sci. Technol. | pmid:27438991 |
| Luo XF et al. | Establishment of a nested-ASP-PCR method to determine the clarithromycin resistance of Helicobacter pylori. | 2016 | World J. Gastroenterol. | pmid:27433095 |
| Sakurai Y et al. | Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover Study. | 2016 | Adv Ther | pmid:27432383 |
| Inagaki K et al. | Successful Treatment of Peritoneal Dialysis-related Peritonitis due to Mycobacterium iranicum. | 2016 | Intern. Med. | pmid:27432106 |
| Shiratori S et al. | Two Cases of Chronic Gastritis with non-Helicobacter pylori Helicobacter Infection. | 2016 | Intern. Med. | pmid:27432094 |
| Furuta K et al. | 18 Cases of pulmonary Mycobacterium abscessus: Clinical difference depending on the presence or absence of Mycobacterium avium complex. | 2016 | J. Infect. Chemother. | pmid:27430867 |
| Hirasawa K et al. | Macrolide Antibiotics Exhibit Cytotoxic Effect under Amino Acid-Depleted Culture Condition by Blocking Autophagy Flux in Head and Neck Squamous Cell Carcinoma Cell Lines. | 2016 | PLoS ONE | pmid:27977675 |
| Mougari F et al. | Infections caused by Mycobacterium abscessus: epidemiology, diagnostic tools and treatment. | 2016 | Expert Rev Anti Infect Ther | pmid:27690688 |
| Okano Y et al. | Miliary pulmonary nodules due to Mycobacterium xenopi in a steroid-induced immunocompromised patient successfully treated with chemotherapy: a case report. | 2016 | BMC Pulm Med | pmid:27287608 |
| Steurer J | [Months of antibiotic therapy in persistent symptoms of Lyme disease without effect]. | 2016 | Praxis (Bern 1994) | pmid:27269781 |
| Chung JW et al. | Ten-day empirical sequential or concomitant therapy is more effective than triple therapy for Helicobacter pylori eradication: A multicenter, prospective study. | 2016 | Dig Liver Dis | pmid:27257049 |
| Mitchell H and Katelaris P | Epidemiology, clinical impacts and current clinical management of Helicobacter pylori infection. | 2016 | Med. J. Aust. | pmid:27256648 |
| Ullah S et al. | Development of a biocompatible creatinine-based niosomal delivery system for enhanced oral bioavailability of clarithromycin. | 2016 | Drug Deliv | pmid:27247018 |
| Kuo CH et al. | A Rapid and Accurate Method to Evaluate Helicobacter pylori Infection, Clarithromycin Resistance, and CYP2C19 Genotypes Simultaneously From Gastric Juice. | 2016 | Medicine (Baltimore) | pmid:27227911 |
| Sluch IM et al. | Mycobacterium chelonae Scleral Abscess After Intravitreal Ranibizumab Injection. | 2016 | Cornea | pmid:27227391 |
| Laird-Fick HS et al. | Gastric adenocarcinoma: the role of Helicobacter pylori in pathogenesis and prevention efforts. | 2016 | Postgrad Med J | pmid:27222587 |
| Phiphatpatthamaamphan K et al. | Effect of IL-1 Polymorphisms, CYP2C19 Genotype and Antibiotic Resistance on Helicobacter pylori Eradication Comparing Between 10-day Sequential Therapy and 14-day Standard Triple Therapy with Four-Times-Daily-Dosing of Amoxicillin in Thailand: a Prospective Randomized Study. | 2016 | Asian Pac. J. Cancer Prev. | pmid:27221874 |
| Parize P et al. | Induction therapy with linezolid/clarithromycin combination for Mycobacterium chelonae skin infections in immunocompromised hosts. | 2016 | J Eur Acad Dermatol Venereol | pmid:25677464 |
| Kim SY et al. | Successful antibiotic treatment of pulmonary disease caused by Mycobacterium abscessus subsp. abscessus with C-to-T mutation at position 19 in erm(41) gene: case report. | 2016 | BMC Infect. Dis. | pmid:27188784 |
| Suzuki S et al. | The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy. | 2016 | Am. J. Gastroenterol. | pmid:27185079 |
| Xu J et al. | Preparation, characterization and pharmacokinetics evaluation of clarithromycin-loaded Eudragit(®) L-100 microspheres. | 2016 | Eur J Drug Metab Pharmacokinet | pmid:25652786 |
| Kazama I et al. | Clarithromycin Dose-Dependently Stabilizes Rat Peritoneal Mast Cells. | 2016 | Chemotherapy | pmid:27088971 |
| Huynh VA et al. | [Fixed drug eruption to clarithromycin: The importance of challenge tests in diagnosis]. | 2016 | Ann Dermatol Venereol | pmid:27080820 |
| EmiralioÄŸlu N et al. | Pulmonary Mycobacterium abscessus Infection in a Patient with Triple A Syndrome. | 2016 | J. Trop. Pediatr. | pmid:27080471 |
| Graham DY and Dore MP | Helicobacter pylori therapy: a paradigm shift. | 2016 | Expert Rev Anti Infect Ther | pmid:27077447 |
| Song ZQ et al. | Hybrid Therapy Regimen for Helicobacter Pylori Eradication. | 2016 | Chin. Med. J. | pmid:27064046 |
| Matsumoto H et al. | Molecular Detection of H. pylori Using Adherent Gastric Mucous to Biopsy Forceps. | 2016 | Helicobacter | pmid:27061611 |
| Tsaganos T et al. | Clarithromycin Leads to Long-Term Survival and Cost Benefit in Ventilator-Associated Pneumonia and Sepsis. | 2016 | Antimicrob. Agents Chemother. | pmid:27044546 |
| Buchicchio A et al. | Biodegradation of carbamazepine and clarithromycin by Trichoderma harzianum and Pleurotus ostreatus investigated by liquid chromatography - high-resolution tandem mass spectrometry (FTICR MS-IRMPD). | 2016 | Sci. Total Environ. | pmid:27039063 |
| Melia MT and Auwaerter PG | Time for a Different Approach to Lyme Disease and Long-Term Symptoms. | 2016 | N. Engl. J. Med. | pmid:27028918 |
| Berende A et al. | Randomized Trial of Longer-Term Therapy for Symptoms Attributed to Lyme Disease. | 2016 | N. Engl. J. Med. | pmid:27028911 |
| D'Erme AM et al. | Successful treatment of rosacea fulminans in a 59-year-old woman with macrolide antibiotics and prednisone. | 2016 | Int. J. Dermatol. | pmid:27028670 |
| Klesiewicz K et al. | Anti-Helicobacter pylori activity of some newly synthesized derivatives of xanthone. | 2016 | J. Antibiot. | pmid:27025351 |
| Kawashima K et al. | Successful eradication of Helicobacter pylori infection with vonoprazan-based triple therapy after failure of PPI-based triple therapy. | 2016 | Dig Liver Dis | pmid:27012448 |
| Ormeci A et al. | Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole. | 2016 | Eur Rev Med Pharmacol Sci | pmid:27010145 |
| Dubini M et al. | Multiple drug allergy: A case of anaphylaxis to levofloxacin but tolerance to ciprofloxacin. | 2016 | Ann. Allergy Asthma Immunol. | pmid:27009438 |
| Miyashita N et al. | Macrolide Therapy for Prevention of Exacerbation in Individuals with Diffuse Aspiration Bronchiolitis. | 2016 | J Am Geriatr Soc | pmid:27000351 |
| Shichijo S et al. | Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after Helicobacter pylori eradication. | 2016 | Gastrointest. Endosc. | pmid:26995689 |
| Belz D et al. | Mycobacterium marinum infection initially diagnosed as metastatic Crohn's disease. | 2016 | J Eur Acad Dermatol Venereol | pmid:25510444 |
| Chua CS et al. | The efficacy of blueberry and grape seed extract combination on triple therapy for Helicobacter pylori eradication: a randomised controlled trial. | 2016 | Int J Food Sci Nutr | pmid:26883189 |
| Meng X et al. | [Antibiotic resistance of Helicobacter pylori clinical isolates in Hebei Province]. | 2016 | Zhonghua Yi Xue Za Zhi | pmid:26879786 |
| Bakshi SS | Outcome evaluation of clarithromycin, metronidazole and lansoprazole regimens in Helicobacter pylori positive or negative children with resistant otitis media with effusion. | 2016 | J Laryngol Otol | pmid:26878377 |
| Franceschi F et al. | High dose amoxicillin-based first line regimen is equivalent to sequential therapy in the eradication of H. pylori infection. | 2016 | Eur Rev Med Pharmacol Sci | pmid:26875899 |
| Tepeš B et al. | Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradication. | 2016 | Eur J Gastroenterol Hepatol | pmid:26862930 |
| Lim SG et al. | The relationship between the failure to eradicate Helicobacter pylori and previous antibiotics use. | 2016 | Dig Liver Dis | pmid:26856963 |
| Niv Y | Doxycycline in Eradication Therapy of Helicobacter pylori--a Systematic Review and Meta-Analysis. | 2016 | Digestion | pmid:26849820 |
| Song Z et al. | Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy. | 2016 | Dig Liver Dis | pmid:26847964 |
| Vannarath S et al. | Antibiotic Resistant Pattern of Helicobacter Pylori Infection Based on Molecular Tests in Laos. | 2016 | Asian Pac. J. Cancer Prev. | pmid:26838225 |
| Miyamoto S et al. | Analysis of Helicobacter pylori genotypes in clinical gastric wash samples. | 2016 | Tumour Biol. | pmid:26825980 |
| Bohnert JA et al. | Novel Piperazine Arylideneimidazolones Inhibit the AcrAB-TolC Pump in Escherichia coli and Simultaneously Act as Fluorescent Membrane Probes in a Combined Real-Time Influx and Efflux Assay. | 2016 | Antimicrob. Agents Chemother. | pmid:26824939 |
| Kadota T et al. | Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease. | 2016 | BMC Infect. Dis. | pmid:26818764 |
| Gaüzère BA and Malvy D | [Vingt-cinquième réunion du comité local de la Société de pathologie exotique, 24 novembre 2015]. | 2016 | Bull Soc Pathol Exot | pmid:26818816 |
| Topp E et al. | Reduced persistence of the macrolide antibiotics erythromycin, clarithromycin and azithromycin in agricultural soil following several years of exposure in the field. | 2016 | Sci. Total Environ. | pmid:27096634 |
| Li X et al. | Macrolides use and the risk of sudden cardiac death. | 2016 | Expert Rev Anti Infect Ther | pmid:27086751 |
| Thung I et al. | Review article: the global emergence of Helicobacter pylori antibiotic resistance. | 2016 | Aliment. Pharmacol. Ther. | pmid:26694080 |
| Vermeer LM et al. | Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters. | 2016 | Drug Metab. Dispos. | pmid:26668209 |
| Meng Y et al. | Multi-functional Liposomes Enhancing Target and Antibacterial Immunity for Antimicrobial and Anti-Biofilm Against Methicillin-Resistant Staphylococcus aureus. | 2016 | Pharm. Res. | pmid:26666773 |
| Konstantinidis T et al. | Immunomodulatory Role of Clarithromycin in Acinetobacter baumannii Infection via Formation of Neutrophil Extracellular Traps. | 2016 | Antimicrob. Agents Chemother. | pmid:26643338 |
| Ferro BE et al. | Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin. | 2016 | Antimicrob. Agents Chemother. | pmid:26643335 |
| Boyanova L et al. | Clarithromycin Resistance Mutations in Helicobacter pylori in Association with Virulence Factors and Antibiotic Susceptibility of the Strains. | 2016 | Microb. Drug Resist. | pmid:26618567 |
| Wu TS et al. | Postcesarean section wound infection caused by Mycobacterium massiliense. | 2016 | J Microbiol Immunol Infect | pmid:26350122 |
| Kamiya K et al. | Erythema multiforme caused by triple therapy with amoxicillin, clarithromycin and vonoprazan for Helicobacter pylori. | 2016 | J. Dermatol. | pmid:26508502 |
| Mark TM and Coleman M | It's Time to Take Clarithromycin Seriously in Multiple Myeloma. | 2016 | Acta Haematol. | pmid:26505907 |
| Qiu XH et al. | Clarithromycin Synergistically Enhances Thalidomide Cytotoxicity in Myeloma Cells. | 2016 | Acta Haematol. | pmid:26505646 |
| Senatore FJ et al. | Helicobacter pylori treatment: Still a work in progress. | 2016 | Postgrad Med | pmid:26490697 |
| Shin WG et al. | Eradication Rates of Helicobacter pylori in Korea Over the Past 10 years and Correlation of the Amount of Antibiotics Use: Nationwide Survey. | 2016 | Helicobacter | pmid:26470999 |
| Cerqueira RM et al. | How Effective Is the Quadruple Concomitant Helicobacter Pylori Eradication Therapy for Obese Patients Undergoing Gastric Bypass Surgery? | 2016 | Obes Surg | pmid:26467690 |
| Boyanova L et al. | Helicobacter pylori resistance to six antibiotics by two breakpoint systems and resistance evolution in Bulgaria. | 2016 | Infect Dis (Lond) | pmid:26465202 |
| Narita M et al. | Antimicrobial Susceptibility of Microorganisms Isolated from Periapical Periodontitis Lesions. | 2016 | Bull. Tokyo Dent. Coll. | pmid:27665691 |
| Lee J et al. | A new anti-microbial combination prolongs the latency period, reduces acute histologic chorioamnionitis as well as funisitis, and improves neonatal outcomes in preterm PROM. | 2016 | J. Matern. Fetal. Neonatal. Med. | pmid:26373262 |
| Ghaith D et al. | Mutations affecting domain V of the 23S rRNA gene in Helicobacter pylori from Cairo, Egypt. | 2016 | J Chemother | pmid:26358218 |
| Yoon H et al. | Effects of N-acetylcysteine on First-Line Sequential Therapy for Helicobacter pylori Infection: A Randomized Controlled Pilot Trial. | 2016 | Gut Liver | pmid:26347514 |
| Liou JM et al. | Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of in the community and hospital populations: a randomised trial. | 2016 | Gut | pmid:26338825 |
| Tsujimae M et al. | A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori. | 2016 | Digestion | pmid:28030862 |